New hope for rare bleeding disorder: Single-Dose rituximab may replace daily chemo
NCT ID NCT03384277
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested two treatments for acquired hemophilia A, a rare condition where the immune system attacks clotting factor VIII. 66 adults received either steroid plus a single dose of rituximab or steroid plus daily cyclophosphamide. The goal was to see which combination clears the harmful antibody faster and keeps it away longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- steroid (methylprednisolone) combined with either rituximab or cyclophosphamide
- What this could lead to
- If successful, this could show that a single dose of rituximab works as well as daily cyclophosphamide for clearing the harmful antibody, offering a simpler treatment option.
- What could go wrong
- This is a small, completed Phase 4 trial with only 66 participants, so results may not apply to all patients. Both treatments have risks like infection and side effects from steroids.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ethics Committee of Blood disease hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300020, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.